<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03519815</url>
  </required_header>
  <id_info>
    <org_study_id>2018-00462</org_study_id>
    <nct_id>NCT03519815</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate the Efficacy of Ectoin® Containing Eye Spray for Treatment of Dry Eye Disease</brief_title>
  <official_title>Prospective Randomized Study to Evaluate the Efficacy and Tolerability of Ectoin® Containing Eye Spray (EES09) and Comparison to the Liposomal Eye Spray Tears Again® (TA) in the Treatment of Dry Eye Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Applied Sciences and Arts Northwestern Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Applied Sciences and Arts Northwestern Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjective and objective evaluation of the efficacy and tolerability of preservative-free
      &quot;Ectoin® Eye Spray - Colloidal&quot; and comparison of the efficacy and tolerability between
      &quot;Ectoin® Eye Spray - Colloidal&quot; and Tears Again® in patients with mild-moderate dry eye
      disease
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      &quot;Dry eye is a multifactorial disease of the ocular surface characterized by a loss of
      homeostasis of the tear film, and accompanied by ocular symptoms, in which tear film
      instability and hyperosmolarity, ocular surface inflammation and damage, and neuro- sensory
      abnormalities play etiological roles.&quot; (DEWS II Report, 2017).

      For the treatment and prevention of dry eye disease (DED) there are a number of treatment
      modalities available, depending on the severity and classification (aqueous deficient /
      evaporative) of the disease. The liposomal eye spray Tears Again® (TA, Optima Medical Swiss
      AG - medical device with CE marking) represents an option to treat mild to moderate
      evaporative DED. A novel preservative-free eye spray, Ectoin® Eye Spray - Colloidal (EES09;
      bitop AG -medical device with CE marking), was developed, in which colloids (colloidal
      lecithin emulsion) serve as a carrier for Ectoin. Ectoin is known as a natural
      cell-protective and inflammatory-inhibiting molecule. The principle mode of action of Ectoin
      is based on the physical interaction of this compatible solute with water and the resulting
      effects of the Ectoin-Hydro-Complex on the tissue treated.

      The aim of this study is to subjectively and objectively evaluate the efficacy and
      tolerability of preservative-free &quot;Ectoin® Eye Spray - Colloidal&quot; and to compare the efficacy
      and tolerability between &quot;Ectoin® Eye Spray - Colloidal&quot; and Tears Again® in patients with
      mild-moderate dry eye disease.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in subjective variables 10min after application and after the treatment period with the eye sprays, in comparison to baseline measurements (visit 1).</measure>
    <time_frame>10min</time_frame>
    <description>ocular surface disease index (OSDI) questionnaire, VAS questionnaire for evaluation of dry eye symptoms and tolerability of the eye spray.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in tear film quality</measure>
    <time_frame>10min</time_frame>
    <description>non-invasive tear film break up time (NIBUT)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in tear film osmolarity</measure>
    <time_frame>10min</time_frame>
    <description>osmolarity measurement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in conjunctival bulbar redness</measure>
    <time_frame>10min</time_frame>
    <description>grading of conjunctival bulbar redness</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in subjective variables after the treatment period between the two eye sprays.</measure>
    <time_frame>10 +/- 3 days</time_frame>
    <description>ocular surface disease index (OSDI) questionnaire, VAS questionnaire for evaluation of dry eye symptoms and tolerability of the eye spray.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in tear film quality</measure>
    <time_frame>10 +/- 3 days</time_frame>
    <description>non-invasive tear film break up time (NIBUT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in tear film osmolarity</measure>
    <time_frame>10 +/- 3 days</time_frame>
    <description>osmolarity measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in conjunctival bulbar redness</measure>
    <time_frame>10 +/- 3 days</time_frame>
    <description>grading of conjunctival bulbar redness</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>Ectoin Eye Spray</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eye Spray to be applied 3 times per day for the duration of 10 +/-3 days &quot;Ectoin® Eye Spray - Colloidal&quot; (EES09; bitop AG) - CE marked medical device
Ingredients: Ectoin®, Soy-Lecithin, Vitamin A, Vitamin E, water, physiological buffer system Indication: to treat mild to moderate dry eye disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liponit Eye Spray</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eye Spray to be applied 3 times per day for the duration of 10 +/-3 days
Liposomal eye spray: Tears Again® (TA, Optima Medical Swiss AG) - CE marked medical device Ingredients: Soy-Lecithin, Sodium Chloride, Ethanol, Phenoxyethanol, Vitamin A-Palmitate, Vitamin E, Aqua purificata Indication: to treat mild to moderate dry eye disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ectoin® Eye Spray - Colloidal</intervention_name>
    <description>eye spray to be applied to the closed eye lid</description>
    <arm_group_label>Ectoin Eye Spray</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Liposomal eye spray Tears Again®</intervention_name>
    <description>eye spray to be applied to the closed eye lid</description>
    <arm_group_label>Liponit Eye Spray</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Minimum age 18 years

          -  OSDI Score of at least 18

          -  NIBUT smaller or equal to 10s in at least one eye

        Exclusion Criteria:

          -  Post-operative trauma or injury

          -  Ocular disease with exception of DED

          -  Hypersensitivity to any of the ingredients in the products used for this study

          -  Contact lens wear 24h before or on the day of study visits

          -  Use of eye drops / other eye sprays on the day of visit 1 or during the duration of
             the study period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniela S Nosch, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Applied Sciences and Arts Northwestern Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniela S Nosch, PhD</last_name>
    <phone>+41 62 957 26 03</phone>
    <email>daniela.nosch@fhnw.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Roland E Joos, PhD</last_name>
    <phone>+41 62 957 26 01</phone>
    <email>roland.joos@fhnw.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institute of Optometry, FHNW</name>
      <address>
        <city>Olten</city>
        <state>Solothurn</state>
        <zip>4600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniela S Nosch, PhD</last_name>
      <phone>+41 62 957 26 03</phone>
      <email>daniela.nosch@fhnw.ch</email>
    </contact>
    <contact_backup>
      <last_name>Roland E Joos, PhD</last_name>
      <phone>+41 62 957 26 01</phone>
      <email>roland.joos@fhnw.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Craig JP, Purslow C, Murphy PJ, Wolffsohn JS. Effect of a liposomal spray on the pre-ocular tear film. Cont Lens Anterior Eye. 2010 Apr;33(2):83-7. doi: 10.1016/j.clae.2009.12.007. Epub 2010 Jan 21.</citation>
    <PMID>20096622</PMID>
  </reference>
  <results_reference>
    <citation>Craig JP, Nelson JD, Azar DT, Belmonte C, Bron AJ, Chauhan SK, de Paiva CS, Gomes JAP, Hammitt KM, Jones L, Nichols JJ, Nichols KK, Novack GD, Stapleton FJ, Willcox MDP, Wolffsohn JS, Sullivan DA. TFOS DEWS II Report Executive Summary. Ocul Surf. 2017 Oct;15(4):802-812. doi: 10.1016/j.jtos.2017.08.003. Epub 2017 Aug 8. Review.</citation>
    <PMID>28797892</PMID>
  </results_reference>
  <results_reference>
    <citation>Dausch D, Lee S, Dausch S, Kim JC, Schwert G, Michelson W. [Comparative study of treatment of the dry eye syndrome due to disturbances of the tear film lipid layer with lipid-containing tear substitutes]. Klin Monbl Augenheilkd. 2006 Dec;223(12):974-83. German.</citation>
    <PMID>17199193</PMID>
  </results_reference>
  <results_reference>
    <citation>Lee S, Dausch S, Maierhofer G, Dausch D. [A new therapy concept for the treatment of dry eye--the usefulness of phospholipid liposomes]. Klin Monbl Augenheilkd. 2004 Oct;221(10):825-36. German.</citation>
    <PMID>15499517</PMID>
  </results_reference>
  <results_reference>
    <citation>Khaireddin R, Schmidt KG. [Comparative investigation of treatments for evaporative dry eye]. Klin Monbl Augenheilkd. 2010 Feb;227(2):128-34. doi: 10.1055/s-0028-1109686. Epub 2009 Sep 15. German.</citation>
    <PMID>19757354</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2018</study_first_submitted>
  <study_first_submitted_qc>April 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2018</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Applied Sciences and Arts Northwestern Switzerland</investigator_affiliation>
    <investigator_full_name>Daniela Nosch</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>dry eye</keyword>
  <keyword>eye spray</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

